Ask AI
ProCE Banner Activity

Emergency Medicine Management of CAR T-Cell and Bispecific Antibody Therapy–Related AEs

Clinical Thought

In this commentary, emergency medicine experts discuss the early recognition and management of CRS and ICANS associated with CAR T-cell and bispecific antibody therapies in the emergency department.

Released: April 22, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for emergency medicine physicians, nurse practitioners, physician associates, registered nurses, and pharmacists involved in the care of cancer patients presenting to the emergency department for care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop the ability to recognize the early signs of CRS and ICANS in patients presenting to the emergency department

  • Gain proficiency in the pharmacologic and non-pharmacologic interventions for managing CRS and ICANS

  • Understand the components of REMS and their relevance in the emergency management of CAR-T therapy patients.

  • Enhance collaborative practice skills to improve communication between emergency department staff and oncology teams regarding CAR-T therapy management.